别嘌呤醇治疗在高尿酸血症人群的遗传标志物研究  

Allopurinol Treatment for Genetic Markers in Hyperuricemia Population

作　　者：李晓颜[1] LI Xiao-yan(Fenyang Hospital Affiliated to Shanxi Medical University,Lyuliang,Shanxi Province,032200 China)

机构地区：[1]山西医科大学附属山西省汾阳医院,山西吕梁032200

出　　处：《中外医疗》2018年第22期121-122,125,共3页China & Foreign Medical Treatment

基　　金：山西省汾阳医院院级重点科研攻关项目(2017004)

摘　　要：目的观察别嘌呤醇治疗在高尿酸血症人群的遗传标志物研究的效果,用于指导高尿酸血症人群的临床用药。方法便利选择2015年7月—2017年6月在该院治疗的高尿酸血症患者138例为研究对象,随机分为对照组和观察组,对照组采用碳酸氢钠进行治疗,观察组采用别嘌呤醇和碳酸钠联合治疗,比较高尿酸血症患者的治疗情况和不良反应等情况。结果观察组中服用别嘌呤醇药疹组患者HLA-B位点进行基因分型,90.69%患者携带HLA-B·5801等位;观察组中26例(37.68%)患者对别嘌呤醇耐受,不耐受患者43例(62.32%),经统计学分析,差异有统计学意义(χ2=32.75,P=0.003 17)。结论采用别嘌呤醇治疗高尿酸血症,不仅将尿酸的临床疗效比较明显,还可以缓解患者的疼痛,提高其的生存质量,病为患者树立对抗疾病的信心,值得临床推广和应用。Objective To observe the effect of allopurinol on the study of genetic markers in hyperuricemia and to guide the clinical use of hyperuricemia. Methods 138 patients with hyperuricemia who were treated in the hospital from July 2015 to June 2017 were convenient selected and randomly divided into control group and observation group. The control group was treated with sodium bicarbonate and the observation group was the combination of purine alcohol and sodium carbonate compared the treatment and adverse reactions of patients with hyperuricemia. Results HLA-B loci were genotyped in patients taking allopurinol and eruption in the observation group, 90.69% of patients were carrying HLA-B·5801 allele; 26 patients（37.68%） in the observation group were tolerant to allopurinol 43 cases（62.32%） were intolerant to the patient. The statistical analysis showed that the difference was statistically significant（χ^2=32.75, P=0.003 17）. Conclusion The use of allopurinol in the treatment of hyperuricemia not only has obvious clinical efficacy, but also relieves the pain of patients and improves their quality of life. The disease provides patients with confidence in fighting diseases and is worthy of clinical promotion and application.

关 键 词：别嘌呤醇 高尿酸血症 血清尿酸 遗传标志物研究 

分 类 号：R4[医药卫生—临床医学]